21st Century Cures From Bench to Market and Who is Paying for it  Jocelyn Kaiser Science Magazine
This diverse panel combines the expertise of researchers from academia, government and industry. Here, Drew Pardoll, director of the Bloomberg~Kimmel Institute, Elad Sharon from the National Cancer Institute and Scott Carmer from NexImmune discuss what their institutions are doing to invest in immunotherapy research. To learn more about this event and to access slides for this presentation please visit: http://www.hopkinsmedicine.org/institute_basic_biomedical_sciences/news_events/2017_The_Frenemy_Within.html